Waters Corporation and Labcorp announced a strategic partnership to expand access to cervical cancer screening using the FDA-approved BD Onclarity HPV Assay across Labcorp's US network starting in late 2026. This collaboration leverages Waters' diagnostic assets and Labcorp's reach, aiming to improve screening adoption and reach underserved populations, representing a moderate positive for both companies' diagnostic and healthcare service segments.
Waters Corporation and Labcorp have announced a strategic partnership to expand cervical cancer screening access in the US. This collaboration involves Labcorp offering the FDA-approved BD Onclarity HPV Assay, leveraging Waters' diagnostic capabilities following its recent acquisition of certain diagnostic assets. The rollout is slated for late 2026. This is a positive development for both companies as it expands Waters' diagnostic market presence and enhances Labcorp's service portfolio, potentially increasing its market share in diagnostic testing. For traders, this represents a long-term growth opportunity for WAT and LH in the diagnostics space, though the late 2026 rollout means immediate market impact may be limited. The key opportunity lies in the potential for increased revenue streams and market penetration in a critical healthcare segment.